Acantholytic pityriasis rubra pilaris associated with topical use of imiquimod 5%: case report and literature review
An. bras. dermatol
;
95(1): 63-66, Jan.-Feb. 2020. graf
Artículo
en Inglés
| LILACS
| ID: biblio-1088728
ABSTRACT
Abstract Topical use of immune response modifiers, such as imiquimod, has increased in dermatology. Although its topical use is well tolerated, it may be associated with exacerbations of generalized cutaneous inflammatory diseases, possibly through the systemic circulation of pro-inflammatory cytokines. This report describes a case of development of pityriasis rubra pilaris, a rare erythematous-papulosquamous dermatosis, in a woman aged 60 years during treatment with imiquimod 5% cream for actinic keratosis. It evolved with erythrodermic conditions and palmoplantar keratoderma, presenting progressive clinical resolution after the introduction of methotrexate. The authors emphasize the importance of recognizing possible systemic reactions associated with the topical use of imiquimod.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Pitiriasis Rubra Pilaris
/
Queratosis Actínica
/
Imiquimod
/
Antineoplásicos
Tipo de estudio:
Factores de riesgo
Límite:
Femenino
/
Humanos
Idioma:
Inglés
Revista:
An. bras. dermatol
Asunto de la revista:
Dermatologia
Año:
2020
Tipo del documento:
Artículo
País de afiliación:
Brasil
Institución/País de afiliación:
Dermoclínica/BR
/
Universidade Estadual de Campinas/BR
Similares
MEDLINE
...
LILACS
LIS